A randomized controlled trial of mindfulness‐based cognitive therapy for bipolar disorder

Perich, Tania; Manicavasagar, Vijaya; Mitchell, Philip B.; Ball, J. R. B.; Hadži-Pavlović, Dušan

doi:10.1111/acps.12033

Cited by 114 publications

(131 citation statements)

References 40 publications

Supporting

Mentioning

121

Contrasting

Unclassified

Order By: Relevance

“…The lack of significant improvement among women with BSD contrasts with results from open trials that have found positive effects of MBCT on depression or anxiety symptoms in bipolar disorder (Weber et al 2010;Miklowitz et al 2009;Deckersbach et al 2012;Ives-Deliperi et al 2013;Williams et al 2008). Our findings are, however, consistent with the single randomized trial of adults with bipolar disorder that found no effects of MBCT compared to usual care on depression or hypomania symptoms over 12-months (Perich et al 2013).…”

Section: Discussionsupporting

confidence: 89%

“…Several other open trials of MBCT have reported effects on depression or anxiety symptoms in patients with bipolar I or II disorder over 3 months (Deckersbach et al 2012;Williams et al 2008). The only randomized trial of MBCT in bipolar disorder, however, showed no significant benefit of the classes compared to usual care on depression or hypomania symptoms over 12-months (Perich et al 2013).…”

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

Mindfulness-Based Cognitive Therapy for Perinatal Women with Depression or Bipolar Spectrum Disorder

et al. 2015

View full text Add to dashboard Cite

The perinatal period is a high-risk time for mood deterioration among women vulnerable to depression. This study examined feasibility, acceptability, and improvement associated with mindfulness-based cognitive therapy (MBCT) in perinatal women with major depressive disorder (MDD) or bipolar spectrum disorder (BSD). Following a diagnostic evaluation, 39 perinatal women with a lifetime history of MDD (n = 27) or BSD (n = 12) enrolled in an 8-week program of MBCT classes (2 h each) that incorporated meditation, yoga, and mood regulation strategies. Participants were pregnant (n = 12), planning pregnancy (n = 11), or up to 1-year postpartum (n = 16). Participants were self-referred and most had subthreshold mood symptoms. Assessments of depression, (hypo)mania, and anxiety were obtained by interview and self-report at baseline, post-treatment and at 1-and 6-month post-treatment. Women with a history of MDD were more likely to complete the classes than women with BSD. Of 32 women who completed the classes, 7 (21.9 %) had a major depressive episode during the 6-month posttreatment follow-up. On average, participants with MDD reported improvements in depression from pre-to post-treatment. Mood improvement was not observed in the BSD group. In the full sample, improvements in depression symptoms across time points were associated with increasing mindful tendency scores. This study was limited by its uncontrolled design, heterogeneous sample, and questionnairebased assessment of mindfulness skills. MBCT may be an important component of care for perinatal women with histories of major depression. Its applicability to perinatal women with BSD is unclear.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 97%

Mindfulness-Based Cognitive Therapy for Perinatal Women with Depression or Bipolar Spectrum Disorder

et al. 2015

View full text Add to dashboard Cite

show abstract

“…One RCT of MBCT involving 95 patients did not demonstrate any difference in relapse prevention compared to a treatment‐as‐usual group, but did reveal fewer anxiety and depressive symptoms in the MBCT arm 115. Coupled with the findings of other smaller studies, this suggests that MBCT may have a role to play in anxiety reduction in BD 75, 116…”

Section: Foundations Of Managementmentioning

confidence: 86%

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

et al. 2018

View full text Add to dashboard Cite

The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published treatment guidelines for bipolar disorder in 2005, along with international commentaries and subsequent updates in 2007, 2009, and 2013. The last two updates were published in collaboration with the International Society for Bipolar Disorders (ISBD). These 2018 CANMAT and ISBD Bipolar Treatment Guidelines represent the significant advances in the field since the last full edition was published in 2005, including updates to diagnosis and management as well as new research into pharmacological and psychological treatments. These advances have been translated into clear and easy to use recommendations for first, second, and third‐ line treatments, with consideration given to levels of evidence for efficacy, clinical support based on experience, and consensus ratings of safety, tolerability, and treatment‐emergent switch risk. New to these guidelines, hierarchical rankings were created for first and second‐ line treatments recommended for acute mania, acute depression, and maintenance treatment in bipolar I disorder. Created by considering the impact of each treatment across all phases of illness, this hierarchy will further assist clinicians in making evidence‐based treatment decisions. Lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, and cariprazine alone or in combination are recommended as first‐line treatments for acute mania. First‐line options for bipolar I depression include quetiapine, lurasidone plus lithium or divalproex, lithium, lamotrigine, lurasidone, or adjunctive lamotrigine. While medications that have been shown to be effective for the acute phase should generally be continued for the maintenance phase in bipolar I disorder, there are some exceptions (such as with antidepressants); and available data suggest that lithium, quetiapine, divalproex, lamotrigine, asenapine, and aripiprazole monotherapy or combination treatments should be considered first‐line for those initiating or switching treatment during the maintenance phase. In addition to addressing issues in bipolar I disorder, these guidelines also provide an overview of, and recommendations for, clinical management of bipolar II disorder, as well as advice on specific populations, such as women at various stages of the reproductive cycle, children and adolescents, and older adults. There are also discussions on the impact of specific psychiatric and medical comorbidities such as substance use, anxiety, and metabolic disorders. Finally, an overview of issues related to safety and monitoring is provided. The CANMAT and ISBD groups hope that these guidelines become a valuable tool for practitioners across the globe.

show abstract

“…Specifically for bipolar disorder, CBT trial results have been characterized as "mixed" and suggest the need for potential schematic changes in therapeutic intervention (Perich, Manicavasagar, Mitchell, Ball, & Hadzi-Pavlovic, 2013). …”

mentioning

confidence: 99%

Contextual Cognitive-Behavioral Therapies Across the Psychosis Continuum

Martins

Castilho

Carvalho

et al. 2017

European Psychologist

View full text Add to dashboard Cite

Considering several etiologic, therapeutic, and comorbidity-related factors, a psychosis continuum model has been proposed for the understanding and treatment of psychotic disorders. Within the new emerging treatment approaches, Contextual Cognitive-Behavioral Therapies (CCBT) seem to hold promise for the psychosis continuum. However, considering their novelty for this specific population, the quality of efficacy evidence remains unclear. Objective: To examine, critically analyze, and summarize the results from studies based on therapeutic models within the CCBT approach (Mindfulness and Acceptance-based interventions, Compassion-Focused Therapy, Dialectical Behavior Therapy, and Metacognitive Therapy) for patients with a diagnosis within the psychosis continuum (schizophrenia, schizoaffective disorder, bipolar disorder). Methods: Three leading electronic databases (MEDLINE/PUBMED; PsycINFO; Cochrane Library), a grey literature database (OpenGrey), and registered clinical trials (ClinicalTrials.Gov) were searched using combinations of key terms regarding the CCBT models and the diagnosis considered.Reference lists of the relevant studies and reviews were searched. Only Randomized Controlled Trials (RCTs) were included. The "Cochrane Risk of Bias Assessment Tool" was used for quality assessment.Results: A total of 17 articles were included. This review was based on a majority of unclear or low risk of bias studies. Benefits regarding clinical variables such as psychotic symptoms, anxiety and depression,

show abstract

A randomized controlled trial of mindfulness‐based cognitive therapy for bipolar disorder

Cited by 114 publications

References 40 publications

Mindfulness-Based Cognitive Therapy for Perinatal Women with Depression or Bipolar Spectrum Disorder

Mindfulness-Based Cognitive Therapy for Perinatal Women with Depression or Bipolar Spectrum Disorder

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

Contextual Cognitive-Behavioral Therapies Across the Psychosis Continuum

Contact Info

Product

Resources

About